Continuation Protocol for Obstructive Sleep Apnea (OSA)

Summary

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.

Timeline

Start

2024-07-03

Primary completion

2026-06-30

Completion

2026-06-30

Drugs

Indications